$GALT News

Galectin Therapeutics Q1 EPS $(0.08) Misses $(0.06) Estimate

Galectin Therapeutics Announces Publication Of Results From NAVIGATE Phase 2b Clinical Trial Evaluating Belapectin In Patients With MASH Cirrhosis And Portal Hypertension In AASLD Flagship Journal Hepatology

Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate

Galectin Therapeutics Option Alert: Jul 17 $5 Calls at the Ask: 3575 @ $0.45 vs 3177 OI; Earnings 3/30 Before Open [est] Ref=$3.015

Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript

Galectin Therapeutics To Host Virtual KOL Event On March 10, Focusing On Unmet Need And Current Treatment Landscape For MASH Cirrhosis And Portal Hypertension

Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains

Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line

Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027

Galectin Therapeutics Announces FDA Converted Co.'s Initial Request For In-Person Or Teleconference To Written Response, Says 'Based on FDA's written feedback, the Company believes there is alignment with the Agency on the patient population proposed for enrollment in a registration trial.'

Galectin Therapeutics Secured $10M Line Of Credit

Galectin Therapeutics shares are trading higher after HC Wainwright & Co. maintained the stock with a Buy rating and raised the price target from $6 to $11.

HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Raises Price Target to $11

Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data

12 Health Care Stocks Moving In Monday's After-Market Session

Galectin Therapeutics: NAVIGATE Data Validates The Fibrosis Thesis

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting

Galectin Therapeutics Highlights Presentation Of Biomarker Analyses From NAVIGATE At AASLD 2025 Annual Meeting

12 Health Care Stocks Moving In Wednesday's After-Market Session